Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

(2022) Don Husereau et al.   BMJ-British Medical Journal

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

(2021) Chi-Leung Chiang et al.   Cancers

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

(2021) Dan Su et al.   JAMA Network Open

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma

(2021) Xin Zhang et al.   JAMA Network Open

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

(2021) Rui Pei et al.   JAMA Network Open

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

(2021) Thomas Yau et al.   LANCET ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma

(2019) Enrique Soto-Perez-de-Celis et al.   Journal of the National Comprehensive Cancer Network

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Hepatocellular carcinoma

(2018) Alejandro Forner et al.   LANCET

Combinations of Bevacizumab With Cancer Immunotherapy

(2018) Daniel S. Chen et al.   CANCER JOURNAL

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis

(2018) Amir Shlomai et al.   PLoS One

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

(2018) Vivek Verma et al.   Journal for ImmunoTherapy of Cancer

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

(2017) Leslie Wilson et al.   THYROID

Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada

(2016) J. Amdahl et al.   Current Oncology

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling

(2016) Claire Williams et al.   MEDICAL DECISION MAKING

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

The economic burden of brain metastasis among lung cancer patients in the United States

(2016) A. Guérin et al.   JOURNAL OF MEDICAL ECONOMICS

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

(2015) Joong-Won Park et al.   LIVER INTERNATIONAL

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective

(2013) Chunyu Li et al.   SUPPORTIVE CARE IN CANCER

The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions

(2013) Seema Kacker et al.   TRANSFUSION

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis

(2012) Victor Barzey et al.   JOURNAL OF MEDICAL ECONOMICS

Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States

(2011) Dipen A. Patel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast Cancer

(2011) Sophie Lauzier et al.   JOURNAL OF CLINICAL ONCOLOGY

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

(2010) Brian I. Carr et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

(2010) Richard S. Finn et al.   LIVER INTERNATIONAL